ANI PHARMACEUTICALS INC
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
ANIP$67.79+0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Net Revenues | $227,813 | $148,332 | $636,306 | $423,802 |
| Operating Expenses | ||||
| Cost of sales (excluding depreciation and amortization) | 93,389 | 63,075 | 241,041 | 169,930 |
| Research and development | 12,304 | 10,128 | 39,403 | 27,935 |
| Selling, general, and administrative | 76,656 | 79,075 | 234,955 | 179,917 |
| Depreciation and amortization | 22,632 | 15,748 | 68,804 | 45,131 |
| Contingent consideration fair value adjustment | (14,470) | 825 | (25,285) | 1,274 |
| Loss (gain) on disposal of assets | 295 | — | 295 | (5,347) |
| Intangible asset impairment charge | 767 | — | 767 | — |
| Total Operating Expenses, net | 191,573 | 168,851 | 559,980 | 418,840 |
| Operating income (loss) | 36,240 | (20,519) | 76,326 | 4,962 |
| Other Expense, net | ||||
| Unrealized gain on investment in equity securities | 3,140 | 1,355 | 2,551 | 8,298 |
| Interest expense, net | (4,727) | (2,331) | (15,649) | (11,587) |
| Other (expense) income, net | (853) | (2,535) | 1,084 | (2,655) |
| Loss on extinguishment of debt | — | (7,468) | — | (7,468) |
| Income (Loss) Before Income Tax Expense (Benefit) | 33,800 | (31,498) | 64,312 | (8,450) |
| Income tax expense (benefit) | 7,183 | (7,332) | 13,465 | (204) |
| Net Income (Loss) | $26,617 | $(24,166) | $50,847 | $(8,246) |
| Dividends on Series A Convertible Preferred Stock | (344) | (406) | (1,157) | (1,219) |
| Net Income (Loss) Available to Common Shareholders | $26,273 | $(24,572) | $49,690 | $(9,465) |
| Basic and Diluted Income (Loss) Per Share: | ||||
| Basic Income (Loss) Per Share | $1.19 | $(1.27) | $2.26 | $(0.49) |
| Diluted Income (Loss) Per Share | $1.13 | $(1.27) | $2.15 | $(0.49) |
| Basic Weighted-Average Shares Outstanding | 20,074 | 19,404 | 19,840 | 19,275 |
| Diluted Weighted-Average Shares Outstanding | 21,093 | 19,404 | 20,911 | 19,275 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.